Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00002429
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : May 4, 2011
Information provided by:
Bristol-Myers Squibb

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : January 2001
  Actual Study Completion Date : January 2001
  Certification/Extension First Submitted : April 13, 2011
Gathe J, Badero R, Grimwood A, Abrams L, Klesczewski K, Mclaren C. AI454152: Comparison of a Triple Combination Regimen Containing an Enteric Coated Formulation of Didanosine Administered Once-Daily Versus a Regimen of Combivir Plus Nelfinavir. 8th Conference on Retroviruses and Opportunistic Infections, 2001 Feb 4-8. (abstract no 319)